{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T14:30:57Z","timestamp":1777905057469,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Roche (A)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13075-016-1091-1","type":"journal-article","created":{"date-parts":[[2016,8,24]],"date-time":"2016-08-24T13:22:58Z","timestamp":1472044978000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study"],"prefix":"10.1186","volume":"18","author":[{"given":"Martin H.","family":"Stradner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Dejaco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Brickmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winfried B.","family":"Graninger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8939-0505","authenticated-orcid":false,"given":"Hans Peter","family":"Brezinschek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,24]]},"reference":[{"issue":"1","key":"1091_CR1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/clpt.2011.278","volume":"91","author":"DL Scott","year":"2012","unstructured":"Scott DL. Biologics-based therapy for the treatment of rheumatoid arthritis. Clin Pharmacol Ther. 2012;91(1):30\u201343.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"1091_CR2","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793\u2013806.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1091_CR3","doi-asserted-by":"crossref","first-page":"e40362","DOI":"10.1371\/journal.pone.0040362","volume":"7","author":"G Ferraccioli","year":"2012","unstructured":"Ferraccioli G, Tolusso B, Bobbio-Pallavicini F, et al. Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis. PLoS One. 2012;7(7):e40362.","journal-title":"PLoS One"},{"issue":"12","key":"1091_CR4","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/rheumatology\/kep314","volume":"48","author":"L Quartuccio","year":"2009","unstructured":"Quartuccio L, Fabris M, Salvin S, et al. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford). 2009;48(12):1557\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"1091_CR5","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/ard.2010.148759","volume":"70","author":"K Chatzidionysiou","year":"2011","unstructured":"Chatzidionysiou K, Lie E, Nasonov E, et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis. 2011;70(9):1575\u201380.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1091_CR6","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2013-203923","volume":"74","author":"IY Choi","year":"2015","unstructured":"Choi IY, Gerlag DM, Herenius MJ, et al. MRP8\/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74(3):499\u2013505.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1091_CR7","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1002\/art.23902","volume":"58","author":"S Dass","year":"2008","unstructured":"Dass S, Rawstron AC, Vital EM, et al. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum. 2008;58(10):2993\u20139.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1091_CR8","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/art.27359","volume":"62","author":"EM Vital","year":"2010","unstructured":"Vital EM, Dass S, Rawstron AC, et al. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum. 2010;62(5):1273\u20139.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1091_CR9","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/art.30152","volume":"63","author":"EM Vital","year":"2011","unstructured":"Vital EM, Rawstron AC, Dass S, et al. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum. 2011;63(3):603\u20138.","journal-title":"Arthritis Rheum"},{"issue":"101","key":"1091_CR10","doi-asserted-by":"crossref","first-page":"101ra92","DOI":"10.1126\/scitranslmed.3002432","volume":"3","author":"K Owczarczyk","year":"2011","unstructured":"Owczarczyk K, Lal P, Abbas AR, et al. A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis. Sci Transl Med. 2011;3(101):101ra92.","journal-title":"Sci Transl Med"},{"issue":"4","key":"1091_CR11","doi-asserted-by":"crossref","first-page":"R161","DOI":"10.1186\/ar3901","volume":"14","author":"HP Brezinschek","year":"2012","unstructured":"Brezinschek HP, Rainer F, Brickmann K, et al. B lymphocyte-typing for prediction of clinical response to rituximab. Arthritis Res Ther. 2012;14(4):R161.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"1091_CR12","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492\u2013509.","journal-title":"Ann Rheum Dis"},{"issue":"23","key":"1091_CR13","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"IB McInnes","year":"2011","unstructured":"McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205\u201319.","journal-title":"N Engl J Med"},{"issue":"11","key":"1091_CR14","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1002\/art.38107","volume":"65","author":"J Melet","year":"2013","unstructured":"Melet J, Mulleman D, Goupille P, et al. Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response. Arthritis Rheum. 2013;65(11):2783\u201390.","journal-title":"Arthritis Rheum"},{"key":"1091_CR15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/1874312900802010081","volume":"2","author":"M Feuchtenberger","year":"2008","unstructured":"Feuchtenberger M, Muller S, Roll P, et al. Frequency of regulatory T cells is not affected by transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Open Rheumatol J. 2008;2:81\u20138.","journal-title":"Open Rheumatol J"},{"issue":"7","key":"1091_CR16","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1136\/ard.2007.080960","volume":"67","author":"RM Thurlings","year":"2008","unstructured":"Thurlings RM, Vos K, Wijbrandts CA, et al. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis. 2008;67(7):917\u201325.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1091_CR17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315\u201324.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1091_CR18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"AM Gestel van","year":"1996","unstructured":"van Gestel AM, Prevoo ML, van 't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization\/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39(1):34\u201340.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1091_CR19","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/ard.2007.084459","volume":"68","author":"G Wells","year":"2009","unstructured":"Wells G, Becker JC, Teng J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009;68(6):954\u201360.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1091_CR20","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1007\/s00296-015-3295-0","volume":"35","author":"S Piantoni","year":"2015","unstructured":"Piantoni S, Scarsi M, Tincani A, et al. Circulating CD4+ T-cell number decreases in rheumatoid patients with clinical response to rituximab. Rheumatol Int. 2015;35(9):1571\u20133.","journal-title":"Rheumatol Int"},{"issue":"10","key":"1091_CR21","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1002\/art.22943","volume":"56","author":"D Aletaha","year":"2007","unstructured":"Aletaha D, Funovits J, Keystone EC, et al. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum. 2007;56(10):3226\u201335.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1091_CR22","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4049\/jimmunol.1400118","volume":"193","author":"A Palanichamy","year":"2014","unstructured":"Palanichamy A, Jahn S, Nickles D, et al. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J Immunol. 2014;193(2):580\u20136.","journal-title":"J Immunol"},{"issue":"1","key":"1091_CR23","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4049\/jimmunol.160.1.51","volume":"160","author":"O Chan","year":"1998","unstructured":"Chan O, Shlomchik MJ. A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr\/lpr mice. J Immunol. 1998;160(1):51\u20139.","journal-title":"J Immunol"},{"issue":"4","key":"1091_CR24","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.4049\/jimmunol.1302661","volume":"192","author":"I Misumi","year":"2014","unstructured":"Misumi I, Whitmire JK. B cell depletion curtails CD4+ T cell memory and reduces protection against disseminating virus infection. J Immunol. 2014;192(4):1597\u2013608.","journal-title":"J Immunol"},{"issue":"2","key":"1091_CR25","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/art.20858","volume":"52","author":"PP Sfikakis","year":"2005","unstructured":"Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 2005;52(2):501\u201313.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1091_CR26","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/ard.2006.057885","volume":"66","author":"M Tokunaga","year":"2007","unstructured":"Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66(4):470\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1091_CR27","first-page":"499","volume":"84","author":"A Santagostino","year":"1999","unstructured":"Santagostino A, Garbaccio G, Pistorio A, et al. An Italian national multicenter study for the definition of reference ranges for normal values of peripheral blood lymphocyte subsets in healthy adults. Haematologica. 1999;84(6):499\u2013504.","journal-title":"Haematologica"},{"issue":"28","key":"1091_CR28","doi-asserted-by":"crossref","first-page":"10717","DOI":"10.1073\/pnas.0601539103","volume":"103","author":"R Lesley","year":"2006","unstructured":"Lesley R, Kelly LM, Xu Y, et al. Naive CD4 T cells constitutively express CD40L and augment autoreactive B cell survival. Proc Natl Acad Sci U S A. 2006;103(28):10717\u201322.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-016-1091-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T20:45:36Z","timestamp":1692477936000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-016-1091-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,24]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1091"],"URL":"https:\/\/doi.org\/10.1186\/s13075-016-1091-1","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,24]]},"article-number":"190"}}